Periodic Reporting for period 1 - PrasinoMed (First in the world ecological and sustainable cream for wound care, based on microalgaprasinococcus capsulatus)
Reporting period: 2018-08-01 to 2018-11-30
PrasinoTech developed PrasinoSpray, a natural, cost-effective antiviral nasal spray suitable for cold prevention, sustainably manufactured from microalgae. It may also be beneficial for rhinitis suffer
nbavinch ers due to PrasinoMed’s anti-inflammatory properties. The overall objectives of the project are to finalise the formulation and complete a clinical trial to ensure the product is ready for commercial use.
nbavinch ers due to PrasinoMed’s anti-inflammatory properties. The overall objectives of the project are to finalise the formulation and complete a clinical trial to ensure the product is ready for commercial use.
Using SME Instrument Phase 1 funding, the company carried out a Feasibility Study from August 2018 until November 2018. The study explored both the technical and commercial feasibility of a nasal spray, using microalgae Prasinococcus capsulatus. Throughout the project, the company greatly expanded its knowledge of the business model, requirements for clinical validation and regulatory approval for European market launch.
Although mortality/morbidity is rare, common colds are responsible for considerable discomfort, absenteeism from school and work, and healthcare costs. The completion of the proposed project will result in a commercial-ready antiviral nasal spray suitable for cold prevention. The polysaccharide elicits effective and superior anti-viral and anti-inflammatory activity compared to other agents. In addition, PrasinoSpray is 100% natural, avoiding adverse effects of chemical compounds